Palivizumab (RSV) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-094-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
MEDI-493, RSV[Respiratory syncytial virus], RSV[Respiratory syncytial virus]
Background:
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology,directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).Synagis is a composite of human (95%) and murine (5%) antibody sequences.The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2).The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0).Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each),contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF).
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / RSV [Respiratory syncytial virus]
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.